GlassScriptPhysician profile
Tomas Huerta
NPI 1114450889
$5,564.75
in general payments reported to CMS, 2019-2025
24 companies · $2,037 in 2025
The $2,037 reported for 2025 was more than what 88% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $632 · 2023: $1,190 · 2024: $1,705 · 2025: $2,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,763 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,762.91 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $971.32 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $659.79 | 2022-2025 | |
| Amgen INC. | $475.91 | 2022-2025 | Otezla, Otezla, Enbrel |
| E.R. Squibb & Sons, L.L.C. | $453.24 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $348.00 | 2022-2025 | |
| Dermavant Sciences, INC. | $312.26 | 2023-2024 | Vtama |
| Convatec INC. | $288.56 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $284.02 | 2022-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $264.27 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $258.09 | 2022-2025 | |
| Organon LLC | $241.49 | 2025 | Vtama |
| Janssen Biotech, INC. | $239.32 | 2022-2025 | Tremfya |
| Incyte Corporation | $186.96 | 2022-2025 | Opzelura |
| Ucb, INC. | $152.90 | 2022-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $89.96 | 2023-2025 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $85.56 | 2022-2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $79.99 | 2024 | |
| Pfizer INC. | $34.65 | 2022-2025 | |
| Kerecis Limited | $33.63 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Leo Pharma INC. | $24.17 | 2025 | Anzupgo |
| Verrica Pharmaceuticals INC. | $22.43 | 2025 | Ycanth |
| Hydrofera LLC | $22.28 | 2025 | Hydrofera Blue |
| Paratek Pharmaceuticals, INC. | $21.43 | 2025 | Nuzyra |
| Botanix Sb INC | $14.52 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomas Huerta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.